Table 2.
Paraclinical data of the patients at baseline and at the end of follow up
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |||||
| Baseline | mo 6 | Baseline | mo 6 | Baseline | mo 6 | Baseline | mo 61 | |
| Edema | 2+ | None | 2+ | 2+ | 1+ | 1+ | 2+ | – |
| Ascites | Moderate | None | Moderate | Moderate | Moderate | Moderate | Severe | – |
| Serum albumin (g/dL) | 3.8 | 4.2 | 2.9 | 3.1 | 2.5 | 2.8 | 2.6 | – |
| PT (seconds) | 14 | 14.6 | 20.7 | 17 | 18.7 | 16.7 | 19.5 | – |
| INR | 1.2 | 1.3 | 2.2 | 1.8 | 1.9 | 1.6 | 2 | – |
| Cr (mg/dL) | 1.2 | 0.83 | 0.95 | 1.8 | 0.72 | 0.8 | 1.37 | – |
| Total bilirubin (mg/dL) | 1.2 | 1.87 | 3.31 | 5 | 2.37 | 2.02 | 19.85 | – |
| Direct bilirubin (mg/dL) | 0.4 | 0.43 | 2.03 | 2.8 | 0.66 | 0.82 | 13.82 | – |
| AST (IU/mL) | 43 | 52 | 52 | 75 | 62 | 37 | 2202 | – |
| ALT (IU/mL) | 31 | 34 | 23 | 30 | 30 | 15 | 2163 | – |
| AFP (mcg/L) | 4.7 | 3.7 | 3.48 | 5.5 | 1.7 | 3.8 | – | |
| MELD score | 11 | 12 | 20 | 25 | 17 | 14 | 29 | – |
| Liver volume (cm3) | 1205 | 1180 | 960 | NA | 896 | 474 | 1159 | – |
1
Since patient 4 died two weeks after undergoing the procedure. There is no data of her follow up on mo 6;
2
Serum aminotransferases of the patient 4 was less than 3 times of upper limit of normal at screening. PT: Prothrombin time; INR: International normalized ratio; Cr: Serum creatinine; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha fetoprotein; MELD: Model for end stage liver disease. NA: not available.